Safety Review Of Antipsychotics Finds Reasons For More Evaluation In Pediatric Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves Lilly's Zyprexa and AstraZeneca's Seroquel for schizophrenia bipolar disease in the pediatric population.